BeiGene (BGNE)
(Delayed Data from NSDQ)
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$246.04 USD
+12.40 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $246.27 +0.23 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Zacks News
BeiGene (BGNE) Surges: Stock Moves 12.6% Higher
by Zacks Equity Research
BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China
by Zacks Equity Research
Celgene Corporation (CELG) recently entered into a strategic collaboration with China based-BeiGene, Ltd. (BGNE).
BeiGene (BGNE) Surges: Stock Moves 20.8% Higher
by Zacks Equity Research
BeiGene (BGNE) was a big mover last session, as the company saw its shares rise almost 21% on Monday amid huge volumes.